Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma

Tytuł :
Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma
Autorzy :
Furubayashi N
Negishi T
Miura A
Nakamura N
Nakamura M
Pokaż więcej
Temat :
urothelial carcinoma platinum-based chemotherapy pembrolizumab paclitaxel carboplatin organ-specific therapeutic effect
Diseases of the genitourinary system. Urology
RC870-923
Źródło :
Research and Reports in Urology, Vol Volume 12, Pp 455-461 (2020)
Wydawca :
Dove Medical Press, 2020.
Rok publikacji :
2020
Kolekcja :
LCC:Diseases of the genitourinary system. Urology
Typ dokumentu :
article
Opis pliku :
electronic resource
Język :
English
ISSN :
2253-2447
Relacje :
https://www.dovepress.com/organ-specific-therapeutic-effect-of-paclitaxel-and-carboplatin-chemot-peer-reviewed-article-RRU; https://doaj.org/toc/2253-2447
Dostęp URL :
https://doaj.org/article/9f56cdd82a6c403e8c98216991c519f2
Numer akcesji :
edsdoj.9f56cdd82a6c403e8c98216991c519f2
Czasopismo naukowe
Nobuki Furubayashi, Takahito Negishi, Akihiro Miura, Nobutaka Nakamura, Motonobu Nakamura Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, JapanCorrespondence: Nobuki Furubayashi Tel +81-92-541-3231Fax +81-92-551-4585Email furubayashi-jua@umin.ac.jpBackground: To evaluate the organ-specific therapeutic effect of paclitaxel and carboplatin (TC) chemotherapy in patients who failed platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma (UC).Patients and Methods: We retrospectively reviewed the data of patients with metastatic UC who had received TC chemotherapy after the failure of platinum-based chemotherapy and pembrolizumab. The RECIST 1.1 criteria were used to assess the objective response to pembrolizumab and TC chemotherapy at tumor sites.Results: We analyzed 8 patients (male, n=5; female, n=3; median age, 65 years old). All patients except one had visceral metastasis. The median overall survival for TC was 10.9 months (95% confidence interval, 1.0‑12.7 months), and the objective response rate was 25.0% (partial response [PR]: 2 cases). The metastatic organs were the lymph nodes in 5 cases (number of tumor sites: 8), lung in 4 cases (number of tumor sites: 12), liver in 3 cases (number of tumor sites: 14), bone in 3 cases (number of tumor sites: 12), and primary lesion in 3 cases (number of tumor sites: 3). There were no cases of a complete response or progressive disease in any metastatic organs due to TC chemotherapy. A PR was seen in 2 cases of lymph node metastasis (40.0%), 2 cases of lung metastasis (50.0%), and 2 cases of liver metastasis (66.7%). All 3 cases of bone metastasis showed stable disease, as did all 3 cases of primary lesion. Improvement in the therapeutic effect of TC chemotherapy compared with pembrolizumab was observed in 2 cases (40.0%) of lymph node metastasis, 2 cases (50.0%) of lung metastasis, and 1 case (33.3%) of liver metastasis.Conclusion: Lymph node, lung, and liver metastases may respond to TC chemotherapy, even if exacerbated with pembrolizumab after platinum-based chemotherapy in metastatic UC.Keywords: urothelial carcinoma, platinum-based chemotherapy, pembrolizumab, paclitaxel, carboplatin, organ-specific therapeutic effect

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies